title: Biological risk factors for restenosis after percutaneous transluminal coronary angioplasty.
abstract: In an attempt to discern biological (such as thrombotic or fibrinolytic) risk factors in patients developing restenosis after percutaneous transluminal coronary angioplasty, the following factors were measured prior to angiography in a population of 23 patients (20 men, 3 women, mean age 57 +/- 5 yr) treated by a successful angioplasty (gain > 20% and residual stenosis < 50%) for stable angina pectoris and who had a routine angiographic restudy. The following factors were thus assessed: lipid factors: cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B; coagulation factors: fibrinogen, antithrombin III, fibrinopeptide A, factor VIII coagulant, factor VIII antigen, protein C; factors of physiological fibrinolysis: plasminogen, alpha 2-antiplasmin, tissue plasminogen activator and euglobulin clot lysis time before and after venous occlusion, plasminogen activator inhibitor before venous occlusion; and factors of platelet release: beta-thromboglobulin, platelet factor 4. Also studied were clinical characteristics: age, gender, diabetes, hypertension, smoking habits, previous myocardial infarction; angiographic data: global extent of coronary artery disease, location of the stenosis in a bend or branch point, complexity of the lesion, initial and residual stenosis and treatment during follow-up. The coronary angiograms were analyzed by a computer-assisted method with automatic edge detection. On angiographic criteria, 6 patients (restenosis group) were judged to have developed a restenosis (30% decrease in diameter and/or return to a 50% stenosis). The other 17 patients (those without restenosis) were considered to have a persistent success. Apart from age (group without restenosis: 55 +/- 6; restenosis group 61 +/- 5, p < 0.04), there were no differences in clinical, angiographic or treatment variables. There were no differences in lipid factors, but significant differences were observed in hemostatic variables: fibrinogen (without restenosis: 3.18 +/- 0.83; restenosis: 3.83 +/- 0.51 milligrams, p = 0.05), tissue plasminogen activator before venous occlusion (without restenosis: 10.9 +/- 26.8; restenosis: 232.5 +/- 371.2 IU, p < 0.04), euglobulin clot lysis time after venous occlusion (without restenosis: 176.5 +/- 100.5; restenosis: 78.6 +/- 40.2 min, p < 0.05) and for marker of the platelet release: platelet factor 4 (without restenosis: 10.8 +/- 7.9; restenosis: 20.5 +/- 7.5 ng/l, p < 0.04). These findings indicate that patients developing restenosis after coronary angioplasty tend to have an imbalance in the prothrombotic-antithrombotic equilibrium prior to the procedure.
authors.affiliation: Hôpital Cardiologique, Pessac, France.
authors.forename: D
authors.initials: D
authors.lastname: Benchimol
authors.forename: J
authors.initials: J
authors.lastname: Bonnet
authors.forename: H
authors.initials: H
authors.lastname: Benchimol
authors.forename: F
authors.initials: F
authors.lastname: Drouillet
authors.forename: C
authors.initials: C
authors.lastname: Duplaa
authors.forename: T
authors.initials: T
authors.lastname: Couffinhal
authors.forename: C
authors.initials: C
authors.lastname: Desgranges
authors.forename: H
authors.initials: H
authors.lastname: Bricaud
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000592:standards*; D001053:Apolipoproteins / Q000097:blood; D001779:Blood Coagulation Factors / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D015897:Comorbidity; D017023:Coronary Angiography; D048909:Diabetes Complications; D003936:Diagnosis, Computer-Assisted; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D001779:Blood Coagulation Factors; D014280:Triglycerides; D002784:Cholesterol